Radius Pharmaceuticals
Part of Radius Health
CompanyUnited States
Radius Pharmaceuticals develops one asset, approved (ELACESTRANT in er-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer). Mostly small molecule acting on ESR1; based in the United States.
- 1
- Asset
- Furthest stage
- Approved
- 6
- Trials
- 3
- Signals
Pipeline
1Selectively binds estrogen receptor alpha, antagonizing its signaling and promoting its degradation.
Approved, Small molecule, ESR1, er-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, Advanced or Metastatic Breast Cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials6
- Signals3
- Similar companies6